If your health plan denied coverage because a treatment was labeled experimental, investigational, or not proven, the first instinct is often to open a browser and start searching. That reaction makes sense. The problem is that general internet research, by itself, rarely answers the question that actually controls the appeal: what does your plan document say, what evidence did the insurer rely on, and what evidence applies to your exact medical facts?
That distinction matters. Federal appeals rules give many patients a right to internal review and, in many cases, an independent external review when a denial involves medical judgment or an insurer’s determination that a treatment is experimental or investigational. Under HealthCare.gov, many consumers have 180 days to file an internal appeal, and urgent cases may qualify for an expedited path or even a simultaneous request for external review. HealthCare.gov’s internal appeals guidance and CMS’s overview of external appeals lay out those baseline rights.
In this post you’ll learn how to build an appeal around plan language, medical records, specialty support, and procedural rights rather than generic search results. If you want more background on how insurers frame these denials in the first place, our guide on how these coverage exclusions are usually argued may help connect the policy language to the evidence fight that often follows.
<aside> 💡 Scroll to the bottom for every post in this series.
</aside>
A denial for “experimental treatment” usually turns on a narrower question than people expect. It is often not whether the treatment exists, whether some doctors discuss it online, or whether a hospital webpage sounds encouraging. It is more often whether the treatment satisfies the coverage criteria in your plan, for your diagnosis, at your stage of illness, with your prior treatment history, and based on the type of evidence the insurer accepts.
That is one reason appeals built only on printouts from search engines can miss the mark. Broad web results may include marketing pages, outdated studies, anecdotal patient stories, or articles involving a different condition, line of therapy, dosage, or patient population. Even credible information can be too general if it does not address the plan’s stated basis for denial.
The more effective approach often starts with the denial packet itself: the explanation of benefits, the adverse benefit determination, the plan’s definition of “experimental” or “investigational,” and any clinical criteria or technology assessment the insurer used. For employer-sponsored plans, the U.S. Department of Labor’s claims-procedure materials explain that benefit denials and appeals are governed by formal process rules, including access to “relevant” claim documents in many ERISA-covered plans. DOL’s claims procedure guidance and related DOL materials on relevant claim documents are useful starting points.
Before drafting an appeal, it helps to figure out which rules apply. The route can differ depending on whether the coverage is:
This matters because deadlines, external review access, and the agency that oversees the process may vary. CMS explains that consumers can have access to either a state-run or federally administered external review process depending on the coverage arrangement and state rules. CMS’s external review fact sheet and federal external review page give a useful overview.
If the plan is job-based, it may also help to ask whether it is self-funded. CMS notes that people in self-funded plans often deal with the employer or the plan administrator when pursuing reconsideration and appeal. CMS’s action plan for denied claims discusses that distinction.
A strong appeal often begins by slowing down and reading the denial notice line by line. Look for: